Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Mutations in the leucine‐rich repeat kinase‐2 gene (LRRK2) are responsible for some forms of familial as well as sporadic Parkinson's disease (PD). The purpose of this study was to examine the frequency of a single pathogenic mutation (6055G>A) in the kinase domain of this gene in United States and Tunisian familial PD and to compare clinical characteristics between patients with and without the mutation. Standardized case report forms were used for clinical and demographic data collection. We investigated the frequency of the most common substitution of LRRK2 (G2019S, 6055G>A) and its impact on epidemiological and phenotypic features. The frequency of mutations in Tunisian families was 42% (38/91) and in U.S. families 2.6% (1/39), with the unique opportunity to compare homozygous (n = 23) and heterozygous (n = 109) Tunisian carriers of G2019S substitutions. Individuals with G2019S substitutions had an older age at onset but few other differences compared with families negative for the substitution. Patients with LRRK2 mutations had typical clinical features of PD. Comparisons between individuals with heterozygous and homozygous LRRK2 mutations suggested that gene dosage was not correlated with phenotypic differences; however, the estimated penetrance was greater in homozygotes across all age groups. © 2006 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1142 · Cited by 1,313
A common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease
Nichols, W. C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C. A., Michaels, V. E., Reed, T., Rudolph, A., Shults, C. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17828-3 · Cited by 457
Cited by
Parkinson's disease: from monogenic forms to genetic susceptibility factors
Lesage, S., & Brice, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp012 · Cited by 945
Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., et al. (2011) · Nature Communications · doi:10.1038/ncomms1453 · Cited by 486
“However, LRRK2 mutations have incomplete penetrance, even when homozygou”
BackgroundProgressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice
Yue, M., Hinkle, K. M., Davies, P., Trushina, E., Fiesel, F. C., Christenson, T. A., Schroeder, A. S., Zhang, L., Bowles, E., Behrouz, B., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.031 · Cited by 281
Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions
Greggio, E., & Cookson, M. R. (2009) · ASN Neuro · doi:10.1042/an20090007 · Cited by 272
LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study
Hulihan, M. M., Ishihara-Paul, L., Kachergus, J., Warren, L., Amouri, R., Elango, R., Prinjha, R. K., Upmanyu, R., Kefi, M., Zouari, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70116-9 · Cited by 190
Self-citation
Metadata
- Authors
- Ishihara, L., Gibson, R. A., Warren, L., Amouri, R., Lyons, K., Wielinski, C., Hunter, C., Swartz, J. E., Elango, R., Akkari, P. A., Leppert, D., Surh, L., Reeves, K. H., Thomas, S., Ragone, L., Hattori, N., Pahwa, R., Jankovic, J., Nance, M., Freeman, A., Gouider‐Khouja, N., Kefi, M., Zouari, M., Ben Sassi, S., Ben Yahmed, S., El Euch‐Fayeche, G., Middleton, L., Burn, D. J., Watts, R. L., & Hentati, F.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 22
- Issue
- 1
- Pages
- 55-61
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2003198613
- Cited by
- 93
- References
- 3
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. https://app.cochat.ai/papers/10.1002/mds.21180
- The paper
- Ishihara, L., Gibson, R. A., Warren, L., Amouri, R., Lyons, K., Wielinski, C., Hunter, C., Swartz, J. E., Elango, R., Akkari, P. A., Leppert, D., Surh, L., Reeves, K. H., Thomas, S., Ragone, L., Hattori, N., Pahwa, R., Jankovic, J., Nance, M., . . . Hentati, F. (2007). Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Movement Disorders. https://doi.org/10.1002/mds.21180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.